Syncona said its portfolio company Beacon Therapeutics has presented full data from the pivotal VISTA trial of its gene therapy laru-zova in X-linked retinitis pigmentosa. The trial met its primary endpoint at both doses tested, and Beacon plans to begin a rolling regulatory submission in the United States later in 2026.
What was announced
Syncona Limited, the life sciences investor, published an announcement on 12 October 2026. Beacon Therapeutics, one of its portfolio companies, presented results from the pivotal Phase II/III VISTA trial as a late-breaking oral presentation during Retina Subspecialty Day at the American Academy of Ophthalmology (AAO) annual meeting, held in New Orleans from 9 to 12 October 2026.
The trial tested laru-zova, a gene therapy for X-linked retinitis pigmentosa (XLRP). XLRP is a rare inherited retinal disease that causes progressive vision loss and can ultimately lead to blindness. Syncona first announced topline VISTA results on 21 September 2026; the AAO presentation gave the data in more detail.
The trial results
VISTA met its primary endpoint, which was endorsed by the US Food and Drug Administration (FDA): a statistically significant improvement in low luminance visual acuity (LLVA). LLVA is an eye test measuring how well a patient can read an eye chart when a dimming filter is placed in front of the eye.
At month 12, 31.0% of patients in the high-dose group gained at least 15 letters on LLVA (p=0.0019). In the low-dose group, 24.1% reached the same threshold (p=0.0106). No patients in the untreated control group did so.
The trial also showed early and sustained improvement in macular sensitivity, measured by microperimetry, compared with the untreated control. Syncona said this indicates better light detection in the central retina. The safety profile was described as favourable and tolerable, and consistent with earlier trials.
Regulatory path
Beacon plans to engage with global regulators and to begin a rolling Biologics License Application (BLA) to the FDA later in 2026. If approved, laru-zova could become the first approved treatment for XLRP. Approval is not certain.
What it means for Syncona
Syncona valued its holding in Beacon at £183.4m at 30 June 2026. The equity stake was valued at £157.3m on a price-of-recent-investment basis, using Beacon's Series C financing in January 2026 as the latest third-party mark. The remaining £26.1m is deferred consideration, valued on a discounted cash flow basis, which gives Syncona a right to a single-digit percentage of all future XLRP product sales or licensing revenue.
The deferred consideration makes up about 14% of that £183.4m. The 30 June valuation date came before the topline results of 21 September. Syncona said it "intends to publish an updated valuation of the deferred consideration as part of its interim results."
Chris Hollowood, chief executive and chief investment officer of Syncona Investment Management Limited, said: "The presentation of data from the pivotal VISTA trial is an important milestone and further strengthens our confidence in the potential of Beacon's gene therapy, laru-zova. In addition to meeting its primary endpoint, the pivotal data has demonstrated positive outcomes across multiple measures of visual function and a favorable safety profile."
He added: "This is an exciting moment for Beacon and for those living with XLRP."






Please wait processing your request...